Computer-Aided Detection System Developed for Cancer Diagnosis

New computer-aided detection (CAD) technology has been developed, which includes solutions for the dearly detection of breast and colon cancers.

The technology was presented by iCAD, Inc. (Nashua, NH, USA), a provider of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer, during the 100th annual meeting of the Radiological Society of North America (RSNA), held in Chicago (IL, USA), November 30-December 5, 2014. Symposia, posters, and workshops discussed the application of iCAD technologies and workflow solutions for enhanced cancer identification, breast density analysis, and tumor characterization. iCAD’s two-dimensional (2D) mammography, tomosynthesis, and computed tomography colonography (CTC) CAD and workflow technologies was also presented.

“We are pleased to showcase our latest cancer detection technologies at the 100th RSNA meeting. Cancer detection technologies have been proven to help radiologists identify cancer earlier, when there may be more treatment options available,” said Ken Ferry, president and CEO of iCAD. “With medical imaging’s rapid evolution, iCAD continues to build its CAD offerings to ensure that radiologists have access to the most innovative solutions for optimal patient care.”

iCAD showcased the PowerLook advanced mammography platform (AMP) and VeraLook CTC, the first US Food and Drug Administration (FDA)-cleared CAD technology for CTC. PowerLook has grown to include several modules for breast density assessment, dose assessment and advanced analytics since it was introduced in 2012. iCAD also demonstrated a new tomosynthesis workflow tool, as a future product to be released.

The role of volumetric density in adjunctive imaging for women with dense breasts is the topic of numerous poster presentations and workshops. Furthermore, iCAD’s Xoft cervical brachytherapy for gynecologic cancer, magnetic resonance imaging (MRI) imaging for the characterization of pediatric brain tumors and a cloud-based, peer-review platform and workflow solution for large oncology networks was also presented.

iCAD provides a range of upgradeable CAD and workflow solutions to support rapid and accurate detection of breast, prostate, and colorectal cancers.

iCAD’s Xoft Axxent electronic brachytherapy (eBx) system is a painless, noninvasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft system is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer, and gynecologic cancers. The iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments.

Related Links:
iCAD